Should You Buy Valeant Pharmaceuticals (VRX) Ahead of Earnings?
Investors are always looking for stocks that are poised to beat at earnings season and Valeant Pharmaceuticals International, Inc.VRX may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.
That is because Valeant Pharmaceuticals is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. After all, analysts raising estimates right before earnings-with the most up-to-date information possible-is a pretty good indicator of some favorable trends underneath the surface for VRX in this report.
In fact, the Most Accurate Estimate for the current quarter is currently at $2.71 per share for VRX, compared to a broader Zacks Consensus Estimate of $2.68 per share. This suggests that analysts have very recently bumped up their estimates for VRX, giving the stock a Zacks Earnings ESP of 1.12% heading into earnings season.
Why is this Important?
A positive reading for the Zacks Earnings ESP has proven to be very powerful in producing both positive surprises, and outperforming the market. Our recent 10 year backtest shows that stocks that have a positive Earnings ESP and a Zacks Rank #3 (Hold) or better show a positive surprise nearly 70% of the time, and have returned over 28% on average in annual returns (see more Top Earnings ESP stocks here ).
Given that VRX has a Zacks Rank #3 (Hold) and an ESP in positive territory, investors might want to consider this stock ahead of earnings. Clearly, recent earnings estimate revisions suggest that good things are ahead for Valeant Pharmaceuticals, and that a beat might be in the cards for the upcoming report.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.